IRMD · XBRL financial data

Iradimed financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (IRMD's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	31,717	41,815	53,303	65,562	73,242	83,814
Revenue from contracts with customers	31,717	41,815	53,303	65,562	73,242	83,814
Cost of revenue	8,143	9,765	12,021	15,404	16,892	19,490
Gross profit	23,574	32,050	41,282	50,158	56,350	64,324
Research and development	1,903	1,905	2,278	2,859	2,832	2,975
General and administrative	12,269	9,771	10,697	15,122	15,937	17,782
Total operating expenses	24,331	22,232	25,655	30,123	34,385	38,177
Operating income (loss)	(756)	9,818	15,628	20,035	21,965	26,147
Interest income	132	35	582	1,864	2,193	2,009
Other income (expense)	—	—	—	—	164	—
Income tax expense (benefit)	(1,986)	511	3,352	4,545	5,041	5,881
Net income (loss)	1,369	9,325	12,828	17,193	19,234	22,480
Earnings per share, basic USD per share	0.11	0.76	1.02	1.36	1.52	1.77
Earnings per share, diluted USD per share	0.11	0.74	1.02	1.35	1.50	1.75
Weighted average shares, basic thousands of shares	12,124	12,346	12,563	12,603	12,670	12,722
Weighted average shares, diluted thousands of shares	12,440	12,591	12,636	12,723	12,784	12,854

Fiscal years (IRMD's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	50,069	62,000	57,961	49,762	52,234	51,159
Marketable securities	1,909	502	—	—	—	—
Accounts receivable	4,575	5,137	13,275	12,224	10,557	13,667
Inventory	3,934	4,300	5,369	12,821	10,402	11,620
Prepaid and other current assets	772	1,001	631	1,193	2,050	4,757
Total current assets	63,736	76,245	77,490	76,001	75,242	81,203
Property and equipment, net	2,120	2,069	2,400	9,289	16,811	23,856
Right-of-use asset	2,715	2,482	2,205	2,043	155	—
Total assets	71,067	82,881	85,514	92,156	98,326	108,776
Accounts payable	657	783	1,799	1,857	1,896	1,820
Total current liabilities	4,917	6,823	8,554	16,327	8,512	10,180
Lease liability, non-current	2,459	2,206	1,912	1,615	1	—
Total liabilities	9,682	10,708	11,841	20,736	11,507	14,158
Retained earnings	37,669	46,995	47,264	43,258	56,791	64,231
Total stockholders' equity	61,385	72,174	73,673	71,420	86,819	94,618
Total liabilities and equity	71,067	82,881	85,514	92,156	98,326	108,776
Common shares outstanding (cover page) thousands of shares	12,311	12,559	12,593	12,663	12,715	12,783

Fiscal years (IRMD's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	1,369	9,325	12,828	17,193	19,234	22,480
Stock-based compensation	3,962	1,459	1,394	2,187	2,525	2,919
Depreciation and amortization	1,339	1,407	671	765	818	1,166
Net cash from operating activities	5,817	11,258	10,043	13,465	25,624	24,947
Purchases of property and equipment	443	482	823	7,441	8,005	7,765
Net cash from investing activities	247	648	(1,375)	(8,007)	(8,817)	(8,421)
Dividends paid	—	—	12,559	13,223	13,677	15,040
Net cash from financing activities	522	24	(12,706)	(13,657)	(14,336)	(17,601)
Net change in cash	6,587	11,931	(4,039)	(8,199)	2,472	(1,075)

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Iradimed	63,288	24,203	6,997*	12.8M	—	Q3 FY26 10-QSep 30, 2026
Orthofix Medical	103,810	210,933	(6,224)*	40.7M	16.7 quarters	Q2 FY26 10-QJun 30, 2026
Angiodynamics	33,973	80,915	(15,330)	42.1M	2.2 quarters	Q1 FY27 10-QAug 31, 2026
Axogen	328,888	75,834	16,536*	59.7M	—	Q3 FY26 10-QSep 30, 2026
Delcath Systems	47,521	29,133	5,712*	34.7M	—	Q2 FY26 10-QJun 30, 2026
Ceribell	41,989	29,341	(13,078)*	38.8M	7.8 quarters	Q3 FY26 10-QSep 30, 2026
Avanos Medical	65,600	182,200	(12,300)	46.8M	5.3 quarters	Q1 FY26 10-QMar 31, 2026
Cadre Holdings	63,916	202,876	22,933*	42.9M	—	Q3 FY26 10-QSep 30, 2026
Pulse Biosciences	101,620	434	(18,709)*	71.3M	5.4 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.